Innate Pharma notifies availability of press release on IPH4502 Phase 1 dose-escalation enrollment completion

Reuters2026/07/21 05:00

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Innate Pharma posted a press release confirming completion of dose-escalation enrollment in its Phase 1 IPH4502-101 study of Nectin-4 ADC IPH4502.
Preliminary data are expected by year-end from 76 patients, set to guide Phase 1 dose optimization in selected tumor types.
Early readouts show a favorable tolerability profile with limited hematologic toxicity, with preliminary activity seen in heavily pretreated solid tumors.
Trial details: https://clinicaltrials.gov/study/NCT06781983.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260720918688) on July 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Innate Pharma notifies availability of press release on IPH4502 Phase 1 dose-escalation enrollment completion

You may also like

Crypto prices